Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery (TASK-POAF)
Atrial Fibrillation New Onset
About this trial
This is an interventional treatment trial for Atrial Fibrillation New Onset focused on measuring ANTICOAGULANTS, CORONARY ARTERY BYPASS GRAFT, ATRIAL FIBRILLATION, POST OPERATIVE ATRIAL FIBRILLATION, COST-EFECTIVENESS, ANTICOAGULANT THERAPY AFTER NEW ONSET POST OPERATIVE ATRIAL FIBRILLATION
Eligibility Criteria
Inclusion Criteria:
- New atrial/flutter fibrillation / flutter lasting more than 12 hours in the postoperative period of CABG
- Individuals in both sex over the age of 18 years
Exclusion Criteria:
- Inability to sign the free and informed consent form
- Contraindication to anticoagulant therapy
- Renal dysfunction with eGFR less than 30ml / min / 1.73m² or dialysis therapy
- Patients with previous AF
- Pregnancy
- Concomitant valve surgery
Sites / Locations
- Heart Institute - University of São PauloRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Rivaroxaban group
Warfarin group
After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued